Obesity Clinical Trial
— OAGBvsLLbypassOfficial title:
A Multicentre Randomized Controlled Trial Comparing Outcome of Laparoscopic One-anastomosis Gastric Bypass and Laparoscopic Long Biliopancreatic Limb Roux Gastric Bypass for Treatment of Morbid Obesity.
Verified date | March 2021 |
Source | Tartu University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A prospective multicenter randomized controlled trial to compare the outcomes of one-anastomosis gastric bypass to long biliary limb Roux gastric bypass. We plan to enroll up to 500 patients from three different clinics in Estonia. Outcomes are excess weight loss %, impact on type 2 diabetes, hypertension, hyperlipidemia and obstructive sleep apnea. Other outcomes are nutritional deficiencies, occurrence of reflux disease and impact on quality of life. There are planned outpatient visits 1, 5 and 10 years after the surgery to measure the impacts. There are a lot of studies comparing OAGB to standard Roux gastric bypass but non comparing it to long biliary limb gastric bypass.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | December 31, 2036 |
Est. primary completion date | December 31, 2031 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - BMI over 35 and obesity related disease - BMI over 40 - age between 18-60 years - agrees to participate in the study Exclusion Criteria: - age under 18 years or over 60 years - abundant adhesions discovered during the surgery - active upper gastrointestinal ulcer disease - prior bariatric surgery - active symptomatic reflux disease - active psychiatric disease (eg psychosis) |
Country | Name | City | State |
---|---|---|---|
Estonia | Tartu University Hospital | Tartu |
Lead Sponsor | Collaborator |
---|---|
Tartu University Hospital | Fertilitas (private clinic), North Estonia Medical Centre |
Estonia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Excess weight loss % | Calculated loss of the excess weight | 10 years | |
Primary | Impact on type 2 diabetes mellitus | Outcome of type 2 diabetes mellitus after the surgery, measured in change in HbA1c % | 10 years | |
Primary | Impact on type 2 diabetes mellitus | Outcome of type 2 diabetes mellitus after the surgery, measured in usage of medication (same dosage, decreased dosage, insulin to peroral, ended all medication) | 10 years | |
Primary | Impact on hypertensive disease | Outcome of hypertensive disease after the surgery; measured in antihypertensive drug usage (same, decrease, ended) | 10 years | |
Primary | Impact on total cholesterol | Outcome of hyperlipidemias after the surgery, measured in change in levels of total cholesterol (mmol/L). | 10 years | |
Primary | Impact on hyperlipidemia | Outcome of hyperlipidemias after the surgery, measured in change in levels of HDL (mmol/L) | 10 years | |
Primary | Impact on hyperlipidemia | Outcome of hyperlipidemias after the surgery, measured in change in levels of LDL (mmol/L) | 10 years | |
Primary | Impact on hyperlipidemia | Outcome of hyperlipidemias after the surgery, measured in change in levels of triglycerides (mmol/L) | 10 years | |
Primary | Impact on hyperlipidemias | Outcome of hyperlipidemias after the surgery, measured in change in levels of total cholesterol, HDL,LDL and triglycerides | 10 years | |
Secondary | Nutritional deficiencies: anemia | % of subjects having hemoglobin below sex adjusted reference (g/L) and ferritin below sex adjusted references (ug/L) | 10 years | |
Secondary | Nutritional deficiencies | Occurrence of B12 deficiency, measured in % of subjects with vitamin B12 below reference (measures in pmol/L) | 10 years | |
Secondary | GERD | % of subjects reporting reflux disease symptoms and/or PPI usage after the surgery | 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |